What If Oral Care Could Be Smarter?

Ostia Sciences is pioneering phosphorylated lantibiotics—a breakthrough class of antimicrobial peptides that selectively eliminate harmful oral pathogens while preserving beneficial bacteria and enhancing immune response. Their SALI-10® probiotic technology addresses the $500 billion global burden of oral diseases by offering a microbiome-friendly alternative to traditional treatments that disrupt the entire oral ecosystem.

The Opportunity

The global oral health market is projected to reach over $54 billion by 2025, with the oral probiotics segment expected to grow from $2.87 billion to $5.6 billion by 2032. Ostia Science’s SALI-10® technology represents a paradigm shift toward precision oral therapeutics, addressing major unmet needs in both consumer oral care and specialized medical applications like head and neck cancer treatment, where 80% of patients face severe dental toxicity.

The Challenge

Ostia Sciences needed to advance their groundbreaking SALI-10® technology from laboratory validation to clinical proof-of-concept trials. With oral diseases affecting 3.5 billion people globally and current treatments being outdated, expensive, and disruptive to the oral microbiome, they required rigorous clinical validation to demonstrate their phosphorylated lantibiotic technology’s efficacy in treating gingivitis and radiation-induced dental toxicity.

NPC’s Solution

Through NPC’s Proof of Concept funding, Ostia Sciences will conduct two essential clinical trials for Ostia’s SALI-10® technology to demonstrate the safety. This critical support will enable them to validate their phosphorylated lantibiotic approach in rigorous randomized controlled trials, generating the clinical evidence needed for regulatory approval and positioning the product as a safe,effective and first-of-its-kind microbiome-based oral health solution.